In gefitinib-resistant non-small cell lung cancer cells, SNX1 was found to inhibit the endocytosis and degradation of MET whose overexpression was believed to be responsible for gefitinib resistance in non-small cell lung cancer19. Here, MET is linked to non-small cell lung carcinoma.